Industry
Medical - Diagnostics & Research
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Loading...
Open
0.74
Mkt cap
12M
Volume
48K
High
0.77
P/E Ratio
-0.63
52-wk high
5.65
Low
0.70
Div yield
N/A
52-wk low
0.67
Portfolio Pulse from
December 03, 2024 | 1:15 pm
Portfolio Pulse from
November 20, 2024 | 12:00 am
Portfolio Pulse from
November 14, 2024 | 5:45 pm
Portfolio Pulse from Benzinga Insights
October 28, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 3:25 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 8:08 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 12:14 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 6:49 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.